riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
riTUXimab 375 mg/m2 Combination Therapy-21 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma. | 4 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine | |
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine | |
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Chlorambucil, Mitoxantrone, Prednisolone, Rituximab | |
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab |